GlassScriptPhysician profile
Jillian Cowan
NPI 1215504972
$20,017.66
in general payments reported to CMS, 2019-2025
29 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.36 · 2022: $654 · 2023: $3,570 · 2024: $3,865 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $4,365 · Consulting Fee: $2,000 · Education: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,325.48 |
| Travel and Lodging | $4,364.57 |
| Consulting Fee | $2,000.00 |
| Education | $641.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $4,744.79 | 2023-2025 | Zoryve |
| Organon LLC | $2,783.25 | 2025 | Vtama |
| Abbvie INC. | $2,093.50 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,298.26 | 2022-2025 | Sotyktu |
| Ucb, INC. | $1,257.92 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,110.42 | 2023-2025 | Tremfya |
| Genzyme Corporation | $1,053.51 | 2022-2025 | |
| Lilly USA, LLC | $1,050.93 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $667.05 | 2023-2025 | |
| Incyte Corporation | $626.49 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $612.27 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $546.99 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $423.46 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $316.14 | 2023-2025 | Aklief, Oracea, Epsolay |
| Janssen Scientific Affairs, LLC | $314.43 | 2022-2025 | Tremfya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $185.73 | 2023-2025 | |
| Amgen INC. | $176.98 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $161.39 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.30 | 2023-2024 | Spevigo |
| Mallinckrodt Hospital Products INC. | $116.42 | 2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.38 | 2025 | Cabtreo, Siliq, Jublia |
| Regeneron Pharmaceuticals, INC. | $61.90 | 2023 | Dupixent |
| Botanix Sb INC | $49.65 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $33.42 | 2023 | Ycanth |
| Almirall LLC | $27.80 | 2022-2023 | Klisyri |
| Biofrontera INC. | $19.50 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Fresenius Kabi USA, LLC | $17.44 | 2023 | Idacio |
| Kyowa Kirin, INC. | $14.73 | 2024 | Poteligeo |
| Nobelpharma America, LLC | $13.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Cowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.